Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Favipiravir in Severe Influenza
NCT03394209Phase 2Completed
- Sponsor
- Capital Medical University
- Start
- Feb 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of favipiravir in influenza, sponsored by Capital Medical University. Primary endpoint: Proportion of patients with minimum plasma of Favipiravir trough concentration above the MEC at 10 days. Started Feb 2018; status: completed.
02
Drugs
favipiravir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03394209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394209.